RPL36AL

Across TCGA pan-cancer cohorts, RPL36AL mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RPL36AL’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where RPL36AL mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types RPL36AL is over-expressed in tumor.

CCRCC, COAD, and HNSC are the cancer types where RPL36AL tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL36AL mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	+1.089	<.001	12	view →
COAD	Male	All	+0.973	<.001	9	view →
HNSC	All	III,IV	+0.691	<.001	6	view →
LUAD	Male	All	+0.557	<.001	6	view →
OV	All	All	+0.709	.031	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

RPL36AL–CCRCC

Open the CCRCC breakdown →